ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 210

Associations of Clinical Biomarkers with Radiographic Progression of Rheumatoid Arthritis (RA) in African Americans with Early Disease

Emma Astrike-Davis1, Rebecca Cleveland 1, Beth Jonas 1 and Leigh Callahan 1, 1Thurston Arthritis Research Center, Chapel Hill, NC

Meeting: ACR/ARP Annual Meeting 2019

Keywords: rheumatoid arthritis (RA) and biomarkers

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Epidemiology & Public Health Poster I: RA – ARP

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To analyze longitudinal data from the Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis Registry (CLEAR) for the association between biomarkers including the HLA-DRB1 shared epitope (SE), anti-cyclic citrullinated peptide (CCP), and rheumatoid factors IgA and IgM (RFIgA and RFIgM) with changes in radiographic progression from study enrollment (< 2yrs disease duration) to 60-month disease duration. Cross-sectional studies have shown an association between SE, CCP, and RF and disease severity in various cohorts of patients with RA. This study seeks to determine the independent effects of these biomarkers as predictors of radiographic progression among African American patients while controlling for the effects of other comorbidities, socioeconomic factors, age, sex, and RA medication.

Methods: We analyzed data on 194 African American patients with information on biomarkers including SE, CRP, CCP, RFIgA and RFIgM as well as radiographic outcomes including erosion scores and joint space narrowing (JSN) at baseline and after 60 months of disease duration. Radiographic disease progression was determined by increase in disease scores from baseline to 60-month disease duration follow-up, and individuals with severe progression were identified as those in the top worst quintile of disease score increase (Erosion≥1; JSN≥7). Demographics, comorbidities, medications, and measures of SES were also collected at the baseline assessment. Multiple imputation was used to impute missing values. Multivariable multi-level linear and logistic regression models with study site adjusted for as a random effect were used to estimate linear coefficients (β), odds ratios (aOR) and 95% confidence intervals (CI) for disease prevalence and progression in relation to biomarkers at baseline. All models were adjusted for gender, age, BMI, number of comorbidities, cigarette smoking, disease duration at study entry, methotrexate/leflunomide (MTX/LEF) use, education level (< high school [HS] vs ≥ HS), home ownership, professional occupation, as well as simultaneous adjustment for all biomarker predictors.

Results: At baseline the mean age was 51 years, 86% were female, average RA disease duration was 14.05 months, and 64.4% patients were on MTX/LEF (Table 1).  Radiographic measures at baseline and 60 months are shown in Table 2. Beta estimates for the cross-sectional association between baseline biomarkers and baseline radiographic measures are shown in Table 3. Also in Table 3 are odds ratios for the association between baseline biomarkers of interest and severe radiographic progression. Results did not indicate an association of CCP, RF, or SE with severe radiographic progression in this cohort.

Conclusion: Our findings show modest associations between biomarkers and radiographic severity in cross-sectional analyses. However, when analyzing biomarker predictors of radiographic progression, CCP, RFIgM, RFIgA, and SE are not significantly associated with disease progression in African Americans over a 60-month disease duration with early RA. Future larger longitudinal studies are needed to confirm our results.


Emma Table 1

Baseline Characteristics


Emma Table 2

Radiographic measures


Emma Table 3

Cross-sectional and longitudinal results


Disclosure: E. Astrike-Davis, None; R. Cleveland, None; B. Jonas, None; L. Callahan, None.

To cite this abstract in AMA style:

Astrike-Davis E, Cleveland R, Jonas B, Callahan L. Associations of Clinical Biomarkers with Radiographic Progression of Rheumatoid Arthritis (RA) in African Americans with Early Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/associations-of-clinical-biomarkers-with-radiographic-progression-of-rheumatoid-arthritis-ra-in-african-americans-with-early-disease/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-of-clinical-biomarkers-with-radiographic-progression-of-rheumatoid-arthritis-ra-in-african-americans-with-early-disease/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology